Chime Biologics and MedPacto Comes Together to Boost Global Biologics Manufacturing!”

Chime Biologics, a prominent global contract development and manufacturing organization (CDMO) specializing in biologics, has announced a new strategic partnership with MedPacto, a South Korean company listed on KOSDAQ (235980) that focuses on cancer therapeutics. Through this collaboration, MedPacto will utilize Chime Biologics’ expertise to enhance the efficiency of the entire process, from technology transfer to clinical manufacturing in accordance with cGMP standards for Investigational New Drug (IND) submissions. As part of the agreement, Chime Biologics will work on advancing the Chemistry, Manufacturing, and Controls (CMC) development for several preclinical drug candidates.

Chime Biologics is set to enhance its manufacturing capabilities to 100,000 litres, reinforcing its status as a prominent global Contract Development and Manufacturing Organization (CDMO). In line with this growth strategy, the company is making significant strides into the South Korean market, having secured partnerships with various local biotech firms to offer development and manufacturing solutions for antibody therapeutics and biosimilars.

Dr. Jungwon Woo, President of MedPacto, said in a statement,” We are highly impressed by Chime Biologics’development and manufacture expertise, which is crucial in helping us expand into major global markets. Their ability to meet international standards will greatly support our efforts to advance our assets into a new stage. This collaboration is a key step forward, and we look forward to a successful and long-term partnership.”

Dr. Jimmy Wei, President of Chime Biologics, stated, “We are pleased to announce our strategic collaboration with MedPacto, a respected KOSDAQ-listed company with a strong portfolio of first-in-class assets. This partnership marks the beginning of a long-term relationship aimed at advancing pharmaceutical innovation. It aligns with our growth strategy in South Korea and aligns with our commitment to the region’s biopharmaceutical landscape. We look forward to working closely with MedPacto and contributing to the success of their innovative pipeline.”